Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

QLGN - Qualigen Therapeutics, Inc.

3.12
-0.120   -3.846%

Share volume: 6,788
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$3.24
-0.12
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 0%
Dept financing 50%
Liquidity 55%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.70%
1 Month
-3.41%
3 Months
-20.00%
6 Months
1,912.90%
1 Year
670.18%
2 Year
202.91%
Key data
Stock price
$3.12
P/E Ratio 
0.00
DAY RANGE
$3.10 - $3.20
EPS 
-$3.24
52 WEEK RANGE
$0.08 - $5.14
52 WEEK CHANGE
$670.56
MARKET CAP 
2.280 M
YIELD 
N/A
SHARES OUTSTANDING 
12.156 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
3.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$8,248
AVERAGE 30 VOLUME 
$13,245
Company detail
CEO: Michael S. Poirier
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.

Recent news